Wednesday, August 20, 2025 8/20/2025

Resource for Molecular Imaging Agents in Precision Medicine

Award Number: P41EB024495
ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2017
PERIOD OF PERFORMANCE END DATE: 08/31/2029

Group Awards By:

View Award Description

Resource for Molecular Imaging Agents in Precision Medicine - The Resource for Molecular Imaging Agents in Precision Medicine is a transdisciplinary consortium of facilities and expertise centered at Johns Hopkins University. Participants are the Russell H. Morgan Department of Radiology and Radiological Science, the F. M. Kirby Research Center at the Kennedy Krieger Institute, the Sidney Kimmel Comprehensive Cancer Center, and the Department of Biomedical Engineering, with key industrial collaborators in biomedical imaging and pharmaceuticals to ensure widespread dissemination. Our work will synthesize, develop, and deploy precision imaging tools and theranostic agents for early detection, interception, and cure. The long-term objective of the NCBIB is to promote the translation and dissemination of new molecular imaging and theranostic agents and their attendant best practices along the spectrum of cancer, inflammation and immunity. Our proposed work capitalizes on advances made in the past five years in artificial intelligence (AI), new and more sensitive translational imaging devices, nanotechnology, gene manipulation, and new techniques to produce specific molecular affinity agents and will create a scientific ecosystem that can transform the healthcare landscape. Collaborative academic centers such as ours, while steeped in the culture of fundamental discovery, are beginning to pivot toward the development of new work products – working backwards from unmet needs – in the context of increasing academic-industrial partnerships and entrepreneurship. Working closely with our partners, we will leverage these advances in scientific and academic cultural thinking, and provide new materials to our collaborating and service partners, some of whom have worldwide reach, to address pressing and unsolved medical challenges. During the first funding period we consolidated our ability to work together seamlessly as a NCBIB; in this renewal, we have added collaboration with a new local NCBIB that complements our work by providing biological reagents relevant to immunoengineering, offering AI capability, founding one company dedicated to advancing use of AI in molecular imaging and another company for commercialization of imaging and theranostic agents, received FDA approval for an imaging agent (analogs of which are already in use in the NCBIB), and providing precursors, other reagents and IND cross-references to multiple institutions. Our goals for the renewal period are, across four TR&Ds, to develop: new reagents to detect and promote an immune reactive tumor microenvironment (TR&D1); an integrated nanoplatform to manage a variety of cancers (TR&D2); translational imaging agents, theranostics, and software for managing inflammation and/or cancer in the periphery or central nervous system (TR&D3); and a method to use extracellular vesicles as a nanotheranostic platform in neuroinflammation (TR&D4). Together with the Collaborating and Service Projects (CPs and SPs) we will generate next-generation precision platforms, tools, and techniques for tackling problems at the forefront of biomedical research with a focus on those that will lead to near-term translation, as we have done previously.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,354,694 )
2025	2025	THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	002	7	8/15/2025	NON-COMPETING CONTINUATION	$1,354,694
2025	2024	THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	6	2/26/2025	COMPETING CONTINUATION	$600
2025	2021	THE JOHNS HOPKINS UNIVERSITY	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	5	2/26/2025	NON-COMPETING CONTINUATION	-$600
														Subtotal = $1,354,694

Issue Date FY: 2024 ( Subtotal = $1,436,774 )
2024	2024	THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER	5323 HARRY HINES BLVD	DALLAS	TX	75390	DALLAS	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	6	8/29/2024	COMPETING CONTINUATION	$1,436,774
														Subtotal = $1,436,774

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2021	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	5	9/14/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $1,179,527 )
2021	2021	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	5	6/29/2021	NON-COMPETING CONTINUATION	$1,179,527
														Subtotal = $1,179,527

Issue Date FY: 2020 ( Subtotal = $1,203,600 )
2020	2020	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	4	7/30/2020	NON-COMPETING CONTINUATION	$1,203,600
														Subtotal = $1,203,600

Issue Date FY: 2019 ( Subtotal = $1,514,303 )
2019	2019	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	3	9/17/2019	SUPPLEMENT FOR EXPANSION	$310,425
2019	2019	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	3	7/26/2019	NON-COMPETING CONTINUATION	$1,203,878
														Subtotal = $1,514,303

Issue Date FY: 2018 ( Subtotal = $1,368,554 )
2018	2018	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	2	8/31/2018	NON-COMPETING CONTINUATION	$1,368,554
2018	2018	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	001	2	9/14/2018	NON-COMPETING CONTINUATION	$0
														Subtotal = $1,368,554

Issue Date FY: 2017 ( Subtotal = $1,563,638 )
2017	2017	JOHNS HOPKINS UNIVERSITY, THE	3400 N CHARLES ST	BALTIMORE	MD	21218	BALTIMORE CITY	USA	Discovery and Applied Research for Technological Innovations to Improve Human Health	000	1	9/15/2017	NEW	$1,563,638
														Subtotal = $1,563,638

Grand Total All Awards = $9,621,090

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Resource for Molecular Imaging Agents in Precision Medicine

Award Number: P41EB024495

ORGANIZATION: NATIONAL INSTITUTE Of BIOMEDICAL IMAGING & BIOENGINEERING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2017

PERIOD OF PERFORMANCE END DATE: 08/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer